Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
acid, anemia, anticancer, asthenia, AstraZeneca, atypical, Bayer, bidder, billion, calcium, clostridium, correction, counsel, creatine, departure, depict, diabetic, diarrhea, difficulty, diligent, effusion, electrocardiogram, encephalopathy, essential, exacerbate, explicitly, faith, fall, Hagop, hypotension, inflammation, lactic, learn, lipase, lobar, lowest, Lupin, malignant, merger, metaiodobenzylguanidine, MIBG, MOVANTIK, MOVENTIG, muscular, myalgia, neutral, notified, obstructive, orthostatic, phosphate, phosphokinase, placement, pleural, potassium, purpose, QT, recommenced, remote, resected, sensory, sodium, Sunshine, supraventricular, surgically, therewith, Valeant, vertigo, wholesaler, Youssoufian
Removed:
accelerated, accessible, Acknowledgment, Algeta, America, announced, ASA, buyer, declined, deliverable, deterioration, discontinued, Division, earned, eligibility, escalation, failed, finalized, FTE, hand, ICH, inception, intend, Lederle, lesser, light, liquidated, Moody, negotiated, overhead, Partial, paying, pilot, Poor, rated, rating, relief, request, reset, salary, shift, sNDA, sublicensee, temporarily, transition
Filing tables
Filing exhibits
- 10-K Annual report
- 12.1 Exhibit 12.1 Ratio
- 21.1 Exhibit 21.1 Subsidiaries of Progenics Pharmaceuticals, Inc.
- 23.1 Exhibit 23.1 Consent of Ernst & Young LLP
- 31.1 Exhibit 31.1 Certification
- 31.2 Exhibit 31.2 Certification
- 32.1 Exhibit 32.1 Certification
- 32.2 Exhibit 32.2 Certification
- Download Excel data file
- View Excel data file
Related press release
PGNX similar filings
Filing view
External links
Exhibit 12.1
Progenics Pharmaceuticals, Inc.
Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends
(in thousands)
Years Ended December 31, | ||||||||||||||||||||
2014 | 2013 | 2012 | 2011 | 2010 | ||||||||||||||||
Determination of earnings (loss): | ||||||||||||||||||||
Income (loss) from operations | $ | 4,410 | $ | (42,934 | ) | $ | (35,431 | ) | $ | 10,381 | $ | (69.820 | ) | |||||||
Add: | ||||||||||||||||||||
Fixed charges | 373 | 710 | 410 | 695 | 709 | |||||||||||||||
Earnings (loss), as adjusted | $ | 4,783 | $ | (42,224 | ) | $ | (35,021 | ) | $ | 11,076 | $ | (69,111 | ) | |||||||
Fixed charges: | ||||||||||||||||||||
Estimate of interest within rental expense | 373 | 710 | 410 | 695 | 709 | |||||||||||||||
Fixed charges | $ | 373 | $ | 710 | $ | 410 | $ | 695 | $ | 709 | ||||||||||
Preferred stock dividends | $ | - | $ | - | $ | - | $ | - | $ | - | ||||||||||
Ratio of earnings (loss) to fixed charges and preferred stock dividends | 13 | * | * | 16 | * | |||||||||||||||
Coverage deficiency amount for total fixed charges and preferred stock dividends (1) | $ | - | $ | 42,934 | $ | 35,431 | $ | - | $ | 69,820 |
(1) | For the years ended 2010, 2012 and 2013, the Company's coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1. |